Tafenoquine
产品说明书
 |
同义名 : | WR 238605 |
| CAS号 : | 106635-80-7 | |
| 货号 : | A299706 | |
| 分子式 : | C24H28F3N3O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 463.49 | |
| MDL号 : | MFCD00598712 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The 8-aminoquinoline (8AQ) class of anti-malarial compounds is extremely important in the fight against malaria, as this class of molecules is unique due to the efficacy against relapsing forms of malaria. Tafenoquine (TQ) is an 8-aminoquinoline (8AQ) that is currently in late stage development as an anti-malarial prophylactic agent. In the CYP 2D knock-out mouse model, there was no luminescence signal at either 48 or 72 hr post-infection indicating that TQ at its ED100 (3 mg/kg) prevented P. berghei infection. TQ was tested at two times its ED100 in the humanized/CYP 2D6 knock-in mouse strain. The results showed that there was less luminescence signal in all five mice at 48 hr (as compared to WT-infected controls) and no detectable luminescence signal at 72 hr post-inoculation. Five out of five WT mice treated with TQ had no detectable parasite burden after 31 days, in comparison to the WT infection control or the CYP 2D knock-out mice treated with TQ. Those results illustrated that TQ is active in the presence of the CYP 2D gene cluster[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.16mL 0.43mL 0.22mL |
10.79mL 2.16mL 1.08mL |
21.58mL 4.32mL 2.16mL |
| 参考文献 |
|---|